2021 was a challenging year for medical professionals and researchers. We entered the second calendar year of COVID-19 and, while the emergence of reliable and effective vaccines has brought some hope for the future, there remain grand challenges for the world’s global health infrastructures - including vaccine hesitancy and availability for the poorest communities in the world. Now more than ever, it is vital that medical research be open and accessible to all. In this Research Topic, hosted by the Speciality Chief Editor of Translational Medicine, we invited leading researchers to contribute Expert Opinions assessing the current state of the medical fields, evaluating future prospects and stimulating debate.

Belosersky Institute of Physicochemical Biology, Lomonosov Moscow State University

A discussion on how medical research must remain open to all, examining current trends in healthcare and potential prospects.

Frontiers in Medicine

Translational Medicine

Experts' Opinion in Medicine 2022

Introducing personalized therapies requires a better, than implemented currently, coupling of basic research to medicine. The current topic is dedicated to promote this coupling through presenting the basic research that has clear medical implications. The medicine-inspired studies of neurodegenerative diseases (<a href="https://doi.org/10.3389/fmed.2022.1033272">Gibson et al.</a>) and cancer (<a href="https://doi.org/10.3389/fmed.2022.1035335">Cooper et al.</a>; <a href="https://doi.org/10.3389/fmed.2022.1035356">Pokrovsky et al.</a>) demonstrate how the knowledge on molecular mechanisms may improve diagnostics and treatments of human diseases. To support the on-going discussion on artificial-intelligence-based approaches to solve medical challenges, we also include an opinion reflecting on possible advantages and drawbacks of such approaches (<a href="https://doi.org/10.3389/fmed.2022.878281">Mainous III</a>).<a href="https://doi.org/10.3389/fmed.2022.1033272">Gibson et al.</a> discuss results of a pilot clinical trial of benfotiamine (a pharmacological form of thiamine, or vitamin B1) in patients with Alzheimer's disease, regarded in view of impressive amount of data on the role of thiamine in the nervous system. Pharmacological doses of thiamine, i.e. the doses much higher than naturally occurring ones, are required for the positive action of thiamine in the age-associated neurodegenerative diseases. This is most probably due to a multitude of the age-associated factors and conditions altering the thiamine delivery to tissues. As multiple drugs including widely used antidiabetics metformin, compete with thiamine for cellular thiamine transporters (<a href="#B1">1</a>), individual differences in thiamine transporters caused by genetic or epigenetic factors, may increase interpersonal variations in the brain thiamine pool and its response to the administration of thiamine and derivatives. Besides, perturbed thiamine phosphorylation, such as an imbalance in the phosphorylation and dehosphorylation of blood thiamine, is known in the patients with Alzheimer's disease vs. the control group (<a href="#B2">2</a>). Hence, the impaired cellular transport and/or metabolism of thiamine may be compensated by unnaturally high levels of administered thiamine and derivatization into the membrane penetrating forms. In the pilot study, benfotiamine reduces cognitive decline (<a href="#B3">3</a>) and decreases serum indicators of Alzheimer's disease (<a href="#B4">4</a>), when the drug is supplemented at a mild stage. The results support the hypothesis that perturbed metabolism of thiamine is an essential factor in Alzheimer's disease and may be a therapeutic target.The most obvious pathophysiological mechanism of thiamine deficiency is a decrease in glucose metabolism due to insufficient coenzyme form of thiamine, thiamine diphosphate (ThDP). Nevertheless, in Alzheimer's disease patients, the blood activity of thiamine diphosphatase, the enzyme decreasing the levels of the coenzyme ThDP, does not correlate with the fasting glucose levels as strong as the blood activity of thiamine monophosphatase, the enzyme increasing the levels of thiamine monophosphate, does (<a href="#B2">2</a>). Hence, in addition to the essential coenzyme role, a less appreciated non-coenzyme action of thiamine and its non-coenzyme derivatives transported across biological membranes, deserves attention. For example, the binding of ThDP to the master regulator of glucose metabolism, p53, is competitive to that of DNA, resulting in the regulation of p53-dependent transcriptional activity by the coenzyme (<a href="#B5">5</a>). It has also been long known that, apart from the thiamine coenzyme pool, there is a rapidly metabolized pool of thiamine and/or its natural derivatives, participating in neuronal excitation (<a href="#B6">6</a>). Including thiamine triphosphate, the rapidly metabolized pool is involved in the acetylcholine action at synapses, where thiamine co-releases with acetylcholine (<a href="#B7">7</a>, <a href="#B8">8</a>), and a non-coenzyme derivative thiamine triphosphate phosphorylates rapsyn (<a href="#B9">9</a>). Such highly dynamic and local processes may involve only a minor part of the total brain thiamine pool and/or rely on the time-dependent thiamine gradients across membranes. Nevertheless, their utmost importance for the brain function may underly multiple observations that the positive action of thiamine in nervous system may occur without significant increases in the brain levels of the coenzyme ThDP. <a href="https://doi.org/10.3389/fmed.2022.1033272">Gibson et al.</a> draw our attention to this underestimated complexity of the brain action of thiamine.The opinions of <a href="https://doi.org/10.3389/fmed.2022.1035335">Cooper et al.</a> and <a href="https://doi.org/10.3389/fmed.2022.1035356">Pokrovsky et al.</a> consider molecular mechanisms of plasticity of cancer metabolism of amino acids. The more we know about the metabolic differences between the cancer and normal cells, the more cancer-specific or cancer-heightened processes may be employed to fight malformations without significant side effects. For instance, addiction of cancer cells to glutamine provides such a long-known anticancer target as glutaminase. <a href="https://doi.org/10.3389/fmed.2022.1035335">Cooper et al.</a> consider a much less known and underestimated alternative to the glutaminase pathway, where glutamine generates α-ketoglutarate through the ω-amidase pathway. Inhibition of ω-amidase may have minimal effects on normal tissues, but be deleterious to the glutamine-addicted tumors, especially those with elevated expression of the enzyme. Existence of this alternative to the glutaminase pathway may be a reason why the glutaminase inhibitors have not yet resulted in therapeutic applications (<a href="#B10">10</a>). By inducing the alternative ω-amidase pathway, cancer cells may well acquire resistance to the glutaminase-directed drugs. Thus, combinatorial therapies blocking both the glutaminase and ω-amidase pathways may be more successful to kill the glutamine-addicted cancer cells, than the impairment of a single pathway by glutaminase inhibitors.Apart from blocking the enzymes, essential for the amino acid metabolism in cancer cells, one may also deprive cancer cells of essential amino acids. These anticancer approaches and underlying molecular mechanisms are reviewed by <a href="https://doi.org/10.3389/fmed.2022.1035356">Pokrovsky et al.</a>. Several forms of the FDA-approved bacterial asparagine-degrading enzyme asparaginase are currently available for the treatment of acute lymphoblastic leukemia. The ongoing studies also focus on the depletion of L-arginine, L-methionine and L-lysine. Overall, the research has shown that such therapeutic approaches are efficient in the cancer cells that lack the enzymes replenishing the depleted amino acid. Hence, identifying molecular mechanisms of the plasticity of cancer cell metabolism and characterizing expression of the tumor enzymes before, during and after exposure to the amino acid deprivation therapies, is of diagnostic importance (<a href="https://doi.org/10.3389/fmed.2022.1035356">Pokrovsky et al.</a>).Apart from the function of all proteinogenic amino acids as the protein building blocks, that causes high sensitivity to amino acid deprivation in strongly proliferating cells, many amino acids have additional specific roles as participants of different biosynthetic and signaling processes. Sensitivity to deprivation of these amino acids is further elevated, depending on the cancer-cell-specific metabolism. For instance, glutamine is used by cancer cells to generate essential metabolite α-ketoglutarate under hypoxic conditions in the pathways considered above, and as a nitrogen source for biosynthesis of amino acids, nucleotides and antioxidant glutathione. Lysine supports ketogenesis that is activated in some cancer cells to overcome drug action (<a href="#B11">11</a>). Lysine degradation through the DHTKD1-encoded α-ketoadipate dehydrogenase produces glutaryl-CoA for glutarylation of proteins, including those essential for malignant transformation, such as histones (<a href="#B12">12</a>) and pyruvate dehydrogenase complex (<a href="#B13">13</a>). Methionine is required for DNA methylation and for initiating the protein and polyamine synthesis. Remarkably, the α-keto analog of methionine, α-keto-γ-methiolbutyrate, generated in the methionine salvage pathway, is an excellent α-keto substrate for the glutamine transamination in the ω-amidase pathway (<a href="https://doi.org/10.3389/fmed.2022.1035335">Cooper et al.</a>). Hence, blockade of ω-amidase working in tandem with glutamine transaminase, would not only prevent the production of α-ketoglutarate from glutamine through the ω-amidase pathway, but also interfere with the methionine regeneration. Enzymes of the methionine salvage pathway producing α-keto-γ-methiolbutyrate are targets for anticancer therapies (<a href="#B14">14</a>). In this regard, expression of the methionine salvage pathway enzymes linked to ω-amidase, may provide important predictors for anticancer effect of methionine depletion, additional to those considered by <a href="https://doi.org/10.3389/fmed.2022.1035356">Pokrovsky et al.</a>.Thus, basic research on (i) cancer-specific features of the amino acids metabolism, (ii) pathways activated to overcome the amino acid deficiency, and (iii) molecular mechanisms of the cancer cell dependence on specific amino acids, helps to define new anticancer targets, combinatorial therapies and personalized markers to predict the therapies efficacies.Artificial-intelligence-based approaches are supposed to promote the translation of basic research to medicine by providing a better understanding of the disease- or drug-affected pathways (<a href="#B15">15</a>, <a href="#B16">16</a>), particularly those assessed by modern imaging techniques (<a href="#B17">17</a>–<a href="#B20">20</a>). Artificial intelligence may also help patients to learn more about their diseases and the needed control measures. However, one must carefully consider the ways to use the artificial intelligence in the organization and function of health system. Artificial intelligence should not disturb the vital interaction between the doctors and patients. Using an example of Luddites, the expert opinion of <a href="https://doi.org/10.3389/fmed.2022.878281">Mainous III</a> shows that inspirations and progress brought about by new technologies, do not exclude their inappropriate usage. To benefit the well-being of patients, application of the artificial-intelligence-based approaches must help the primary care doctors, but not substitute the doctors. Although the substitution would be cost-effective to benefit insurance companies and corporations, disappearance of the primary care doctors is a disadvantage for patients and society. While earlier the doctors could “sniff” the ketone bodies to diagnose the disease, the current trend is not to provide an expert opinion without prescribing a patient to go through a number of tests. However, what if the tests are not available or the insurance is not appropriate? Elimination of the human expertise in medical examination by analytical tests prescribed through online diagnostics by artificial intelligence will cause unnecessary delays, negatively affecting the time of the first aid. Besides, taken over by the universal formalized approaches of artificial intelligence lacking non-verbal components, the overall accumulated knowledge on personal medical examination will undergo a decay. As a result, <a href="https://doi.org/10.3389/fmed.2022.878281">Mainous III</a> concludes that “the use of virtual-first primary care without a physical exam… is an open question” with the answer far from obvious.VB: Conceptualization, Project administration, Writing&#x2014;original draft, Writing&#x2014;review and editing.Financial support of translational studies of VB by Russian Foundation of Basic Research (RFBR grant N 20-54-7804) is gratefully acknowledged.Many thanks to all the authors who have contributed to this Research Topic, for sharing their expertise, and to the Frontiers team for their assistance with the project.The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Editorial: Experts' opinion in medicine 2022

α-Ketoglutaramate—A key metabolite contributing to glutamine addiction in cancer cells

Amino acid deprivation therapy (AADT) is a promising strategy for developing novel anticancer treatments, based on variations in metabolism of healthy and malignant cells. L-asparaginase was the first amino acid-degrading enzyme that received FDA approval for the treatment of acute lymphoblastic leukemia (ALL). Arginase and arginine deiminase were effective in clinical trials for the treatment of metastatic melanomas and hepatocellular carcinomas. Essential dependence of certain cancer cells on methionine explains the anticancer efficacy of methionine-g-lyase. Along with significant progress in identification of metabolic vulnerabilities of cancer cells, new amino acid-cleaving enzymes appear as promising agents for cancer treatment: lysine oxidase, tyrosine phenol-lyase, cysteinase, and phenylalanine ammonia-lyase. However, sensitivity of specific cancer cell types to these enzymes differs. Hence, search for prognostic and predictive markers for AADT and introduction of the markers into clinical practice are of great importance for translational medicine. As specific metabolic pathways in cancer cells are determined by the enzyme expression, some of these enzymes may define the sensitivity to AADT. This review considers the known predictors for efficiency of AADT, emphasizing the importance of knowledge on cancer-specific amino acid significance for such predictions.

Amino acid deprivation therapy (AADT) is a promising strategy for developing novel anticancer treatments, based on variations in metabolism of healthy and malignant cells. L-asparaginase was the first amino acid-degrading enzyme that received FDA approval for the treatment of acute lymphoblastic leukemia (ALL). Arginase and arginine deiminase were effective in clinical trials for the treatment of metastatic melanomas and hepatocellular carcinomas. Essential dependence of certain cancer cells on methionine explains the anticancer efficacy of methionine-g-lyase. Along with significant progress in identification of metabolic vulnerabilities of cancer cells, new amino acid-cleaving enzymes appear as promising agents for cancer treatment: lysine oxidase, tyrosine phenol-lyase, cysteinase, and phenylalanine ammonia-lyase. However, sensitivity of specific cancer cell types to these enzymes differs. Hence, search for prognostic and predictive markers for AADT and introduction of the markers into clinical practice are of great importance for translational medicine. As specific metabolic pathways in cancer cells are determined by the enzyme expression, some of these enzymes may define the sensitivity to AADT. This review considers the known predictors for efficiency of AADT, emphasizing the importance of knowledge on cancer-specific amino acid significance for such predictions.

Predictive markers for efficiency of the amino-acid deprivation therapies in cancer

Graphical AbstractSummary of the study. <graphic xlink:href="fmed-09-1033272-g0001.tif" xmlns:xlink="http://www.w3.org/1999/xlink" />